CD22 and acute lymphoblastic leukemia: Moreover, targeted cytotoxic drug delivery to CD22-expressing B-ALL cells by the antibody drug conjugate (ADC) Inotuzumab ozogamicin has been proven to be superior to standard therapy in r/r B-ALL [12].